[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369200-105":59,"doc-detail-369200-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","metformin-combined-with-cb-839-specifically-inhibits-kras-mutant-ovarian-cancer","Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer","","KRAS mutations can drive metabolic reprogramming in ovarian cancer, increasing metastatic potential. This study examined how KRAS mutations alter energy and nutrient metabolism and evaluated the mechanism by which metformin combined with the glutaminase 1 inhibitor CB-839 counteracts these changes. KRAS-mutant cells showed elevated glucose- and glutamine-pathway enzymes and greater aerobic oxidative capacity. Combined treatment suppressed KRAS-mutant proliferation and aerobic oxidation more strongly, with enhanced glutamine enzyme expression and stronger effects in a NOD-SCID mouse model than monotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metformin-combined-with-cb-839-specifically-inhibits-kras-mutant-ovarian-cancer/369200/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metformin-combined-with-cb-839-specifically-inhibits-kras-mutant-ovarian-cancer/369200.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What metabolic changes are associated with KRAS-mutant ovarian cancer cells?","Question",{"text":112,"@type":113},"KRAS-mutant ovarian cancer cells display elevated glucose metabolism enzymes and glutamine metabolism enzymes, along with a higher aerobic oxidative capacity than wild-type cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does metformin affect KRAS-mutant ovarian cancer cells?",{"text":117,"@type":113},"Metformin inhibits proliferation, reduces glucose metabolism-related enzyme expression, and lowers aerobic oxidative capacity in KRAS-mutant cells, while increasing glutamine metabolism-related enzyme expression.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the combination of metformin and CB-839 more effective than drug alone?",{"text":121,"@type":113},"Metformin combined with CB-839 inhibits KRAS-mutant cell proliferation and aerobic oxidation to a greater extent than in wild-type cells, and the inhibitory effects in the NOD-SCID mouse model are significantly stronger than those of the single-drug group.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369200,1790284413,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMetformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer  \nHan Wu1, Jialin Zhang1, Qiujie Wang1, Zijiao Li1, Linlin Li2 & Ya Xie1􀀍  \nKRAS mutations can cause metabolic reprogramming in ovarian cancer, leading to an increased metastatic capacity. This study investigated the metabolic reprogramming changes induced by KRAS mutations in ovarian cancer and the mechanism of action of metformin combined with a glutaminase 1 inhibitor (CB-839) . KRAS-mutant ovarian cancer accounted for 14% of ovarian cancers. The expression of glucose metabolism-related (PFKFB3, HK2, GLUT1, and PDK2) and glutamine metabolism-related enzymes (GLS1 and ASCT2) was elevated in KRAS-mutant ovarian cancer cells compared with that in wild-type cells. KRAS-mutant cells had a higher aerobic oxidative capacity than did wild-type cells. Metformin inhibited proliferation, the expression of glucose metabolism-related enzymes, and the aerobic oxidative capacity ofKRAS-mutant cells compared with those of control cells. Furthermore, it enhanced the expression of glutamine metabolism-related enzymes in KRAS-mutant cells. Metformin combined with CB-839 inhibited the proliferation and aerobic oxidation ofKRAS-mutant cells to a greater extent than that observed in wild-type cells. Additionally, the inhibitory effects of metformin and CB-839 in the KRAS-mutant ovarian cancer NOD-SCID mouse model were significantly stronger than those in the drug-alone group. KRAS mutations lead to enhanced glucose and glutamine metabolism in ovarian cancer cells, which was inhibited by metformin combined with CB-839 .  \nKeywords KRAS mutation, Ovarian cancer, Metabolic reprogramming  \nOvarian cancer (OC) is the deadliest gynecological malignancy, with approximately 314,000 new cases and 207,000 deaths per year worldwide1,2. OC has the fourth highest incidence rate and third highest mortality rate among female malignant tumors3, with a 5-year survival rate of \u003C 50%, posing a serious threat to women’s lives and health. This low survival rate is mainly due to the high proliferative potential, chemoresistance, and tumor recurrence rate of OC4. Despite some advances in the treatment of OC, including the use of targeted therapies (poly-ADP ribose polymerase inhibitors), anti-angiogenic drugs, and immune checkpoint inhibitors, which have prolonged the progression-free survival (PFS), the overall survival (OS) of patients with OC has not significantly improved. This may be due to the complexity of the clinical manifestations, biological features, and molecular mechanisms of OC5.  \nGenetic mutations often accompany the development of cancer. Mutated genes drive tumor development by affecting critical cellular functions and homeostasis6. Among the known oncogenes, KRAS has the highest mutation rate. KRAS is associated with a variety of highly lethal cancers, including pancreatic ductaladenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC)7,8, and a large number of studies have demonstrated that its mutations affect cancer cell energy metabolism. Excessive proliferation, invasion, metastasis, and poor prognosis are characteristics of KRAS-mutant OC9, which may imply that KRAS mutation-induced OC has a unique energy metabolism pathway; however, more in-depth studies are needed to confirm this. Therefore, targeting a unique energy metabolism pathway in KRAS-mutant OC is a promising strategy.  \nTumor growth and proliferation are closely related to energy metabolism10. Tumor cells require large amounts of bioenergy during growth and have increased synthetic and redox requirements to maintain rapid proliferation and tumor progression and to enhance their resistance to chemotherapy and radiotherapy11. As a result, cancer cells undergo metabolic reprogramming to meet the demands12, which includes seven main areas: (1) enhanced glycolytic capacity and lactic acid production,","cbCaiqyl6ukeAHoB","https://ap.wps.com/l/cbCaiqyl6ukeAHoB","pdf",2266696,13,"English","# Background and rationale\n## Ovarian cancer burden and treatment limitations\n## KRAS mutations and cancer metabolism\n## Metabolic reprogramming hallmarks\n# Glucose and glutamine metabolic pathways\n## Glucose uptake and the Warburg effect\n## Glutamine catabolism via glutaminase 1","[{\"question\":\"What metabolic changes are associated with KRAS-mutant ovarian cancer cells?\",\"answer\":\"KRAS-mutant ovarian cancer cells display elevated glucose metabolism enzymes and glutamine metabolism enzymes, along with a higher aerobic oxidative capacity than wild-type cells.\"},{\"question\":\"How does metformin affect KRAS-mutant ovarian cancer cells?\",\"answer\":\"Metformin inhibits proliferation, reduces glucose metabolism-related enzyme expression, and lowers aerobic oxidative capacity in KRAS-mutant cells, while increasing glutamine metabolism-related enzyme expression.\"},{\"question\":\"Why is the combination of metformin and CB-839 more effective than drug alone?\",\"answer\":\"Metformin combined with CB-839 inhibits KRAS-mutant cell proliferation and aerobic oxidation to a greater extent than in wild-type cells, and the inhibitory effects in the NOD-SCID mouse model are significantly stronger than those of the single-drug group.\"}]","Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer | PDF",1790181355,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c197075673a0ac3bd995d64fa628610.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edcee1fea9ec084a68e285529178052e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa97443271150cf8892cde0220b46b4b.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fd2afc5a988094502c30c80045be408.webp",980,1287]